Gut Microbiome Integration in Drug Discovery and Development of Small Molecules - INRAE - Institut national de recherche pour l’agriculture, l’alimentation et l’environnement Accéder directement au contenu
Article Dans Une Revue Drug Metabolism and Disposition Année : 2024

Gut Microbiome Integration in Drug Discovery and Development of Small Molecules

Résumé

The ongoing discussion regarding the use of mixed or pure cultures of hydrogenotrophic methanogenic archaea in Power-to-Methane (P2M) bioprocess applications persists, with each option presenting its own advantages and disadvantages. To address this issue, a comparison of methane (CH4) yield between a novel methanogenic archaeon belonging to the species Methanothermobacter marburgensis (strain Clermont) isolated from a biological methanation column, and the community from which it originated, was conducted. This comparison included the type strain M. marburgensis str. Marburg. The evaluation also examined how exposure to oxygen (O2) for up to 240 min impacted the CH4 yield across these cultures. While both Methanothermobacter strains exhibit comparable CH4 yield, slightly higher than that of the mixed adapted culture under non-O2-exposed conditions, strain Clermont does not display the lag time observed for strain Marburg.

Dates et versions

hal-04630522 , version 1 (01-07-2024)

Identifiants

Citer

Patrick Jimonet, Céline Druart, Stéphanie Blanquet-Diot, Lilia Boucinha, Stephanie Kourula, et al.. Gut Microbiome Integration in Drug Discovery and Development of Small Molecules. Drug Metabolism and Disposition, 2024, 52 (4), pp.274-287. ⟨10.1124/dmd.123.001605⟩. ⟨hal-04630522⟩
30 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Mastodon Facebook X LinkedIn More